August 22, 2019 by Steve Blade
A recent report by Fact.MR projects the global colorectal cancer diagnostics market to register an impressive expansion at 8.5% CAGR during the forecast period 2017 to 2022. Revenues from the global colorectal cancer diagnostics market is expected to surpass US$ 2,000 Mn by 2022-end.
There has been a substantial increase in the demand for the colorectal cancer diagnostics, with the outbreak of colon cancer at an alarming rate. Rise in the demand for the diagnostics equipment is evident in the emerging countries, deprived of the robust healthcare infrastructures. Additionally, absence of adjuvant and neoadjuvant agents for the detection of cancer among patients is expected to reflect favorably on the global colorectal cancer diagnostics market.
Request Sample Here:
With the advent of advanced diagnostics tests, government initiatives to control the prevalence of cancer, and adoption of diagnostics therapies, the size of the market is poised to surpass the value of US$ 2,000 Mn through 2022. Colorectal cancer, being the third-most prevalent cancer across the world, the demand for acute diagnostics tool has been surging, especially in the developed economies. Advanced screening methodologies in the market are further anticipated to be a strong driver for the growth of this market.
Table of Content
1. Global Colorectal Cancer Diagnostics Market - Executive Summary
2. Global Colorectal Cancer Diagnostics Market Overview
3. Global Colorectal Cancer Diagnostics Market Analysis and Forecast By Test Type
To be Continue..............
Colorectal Cancer Diagnostics Market: Geographical Split and Competitive Dynamics
North America will continue to be the most lucrative region for the colorectal cancer diagnostics market. Revenue from market in North America is expected to surpass US$ 800 Mn by 2022-end.
The behemoths analyzed in this report consists of Foundation Medicine, Inc., Illumina, Inc., Sysmex Corporation, Danaher Corporation, Cancer Genetics, Inc., Exact Science Corporation, Biocept, Inc, Rosetta Genomics, Pathway Genomics Corporation, and Epigenomics AG. An in-depth evaluation has been made on these leading players that are dominating the colorectal cancer diagnostics market has been included in the report, along with its revenue, recent M&A, and product offerings.
For More Information Raise Enquiry
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
11140 Rockville Pike
Rockville, MD 20852